Archives of Pharmacal Research

, Volume 33, Issue 10, pp 1557–1565 | Cite as

How to overcome retinal neuropathy: The fight against angiogenesisrelated blindness



The retina consists of neuronal cells of high metabolic activity that are supplied by an abundant vasculature. It is a main theme of ophthalmologic research, because retinopathies are common causes of blindness in all age groups: age-related macular degeneration in the elderly, diabetic retinopathy in the middle aged, and retinopathy of prematurity and retinoblastoma in children. Interestingly, angiogenesis underlies the pathogenesis of all these diseases, and breakdown of the blood-retinal barrier is also thought to play an important role before and throughout the process of new vessel formation. However, so far, most treatments have targeted angiogenesis only, especially vascular endothelial growth factor. Consideration of the restoration of the blood-retinal barrier should be required. In this review, we discuss the clinical manifestation, pathogenesis, and current treatment options for angiogenesis-related blindness. In addition, because of the recent introduction of novel strategies, we describe pathogenesis-based treatment options to treat angiogenesis-related blindness.

Key words

Angiogenesis-related blindness Age-related macular degeneration Diabetic retinopathy Retinoblastoma Retinopathy of prematurity 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abcouwer, S. F., Shanmugam, S., Gomez, P. F., Shushanov, S., Barber, A. J., Lanoue, K. F., Quinn, P. G., Kester, M., and Gardner, T. W., Effect of IL-1beta on survival and energy metabolism of R28 and RGC-5 retinal neurons. Invest. Ophthalmol. Vis. Sci., 49, 5581–5592 (2008).CrossRefPubMedGoogle Scholar
  2. Abramson, D. H. and Schefler, A. C., Update on retinoblastoma. Retina, 24, 828–848 (2004).CrossRefPubMedGoogle Scholar
  3. Abran, D., Varma, D. R., and Chemtob, S., Increased thromboxane-mediated contractions of retinal vessels of newborn pigs to peroxides. Am. J. Physiol., 268, H628–H632 (1995).PubMedGoogle Scholar
  4. Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., and Park, J. E., Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med., 331, 1480–1487 (1994).CrossRefPubMedGoogle Scholar
  5. Beutel, J., Rudolf, M., and Grisanti, S., Current and future therapies for age-related macular degeneration. Expert Opin. Emerg. Drugs, 14, 341–362 (2009).CrossRefPubMedGoogle Scholar
  6. Bressler, N. M., Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch. Ophthalmol., 119, 198–207 (2001).PubMedGoogle Scholar
  7. Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., and Schneider, S., Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med., 355, 1432–1444 (2006).CrossRefPubMedGoogle Scholar
  8. Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., De Mol, M., Wu, Y., Bono, F., Devy, L., Beck, H., Scholz, D., Acker, T., Dipalma, T., Dewerchin, M., Noel, A., Stalmans, I., Barra, A., Blacher, S., Vandendriessche, T., Ponten, A., Eriksson, U., Plate, K. H., Foidart, J. M., Schaper, W., Charnock-jones, D. S., Hicklin, D. J., Herbert, J. M., Collen, D., and Persico, M. G., Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med., 7, 575–583 (2001).CrossRefPubMedGoogle Scholar
  9. Chen, J. and Smith, L. E., Retinopathy of prematurity. Angiogenesis, 10, 133–140 (2007).CrossRefPubMedGoogle Scholar
  10. Connor, K. M., Sangiovanni, J. P., Lofqvist, C., Aderman, C. M., Chen, J., Higuchi, A., Hong, S., Pravda, E. A., Majchrzak, S., Carper, D., Hellstrom, A., Kang, J. X., Chew, E. Y., Salem, N. Jr., Serhan, C. N., and Smith, L. E., Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat. Med., 13, 868–873 (2007).CrossRefPubMedGoogle Scholar
  11. Cunha-Vaz, J. G., The blood-retinal barriers. Doc. Ophthalmol., 41, 287–327 (1976).CrossRefPubMedGoogle Scholar
  12. Davidson, J. A., Ciulla, T. A., Mcgill, J. B., Kles, K. A., and Anderson, P. W., How the diabetic eye loses vision. Endocrine, 32, 107–116 (2007).CrossRefPubMedGoogle Scholar
  13. De Jong, P. T., Age-related macular degeneration. N. Engl. J. Med., 355, 1474–1485 (2006).CrossRefPubMedGoogle Scholar
  14. Dixon, J. A., Oliver, S. C., Olson, J. L., and Mandava, N., VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. Expert Opin. Investig. Drugs, 18, 1573–1580 (2009).CrossRefPubMedGoogle Scholar
  15. Doukas, J., Mahesh, S., Umeda, N., Kachi, S., Akiyama, H., Yokoi, K., Cao, J., Chen, Z., Dellamary, L., Tam, B., Racanelli-layton, A., Hood, J., Martin, M., Noronha, G., Soll, R., and Campochiaro, P. A., Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J. Cell. Physiol., 216, 29–37 (2008).CrossRefPubMedGoogle Scholar
  16. Edwards, A. O., Ritter, R. 3rd, Abel, K. J., Manning, A., Panhuysen, C., and Farrer, L. A., Complement factor H polymorphism and age-related macular degeneration. Science, 308, 421–424 (2005).CrossRefPubMedGoogle Scholar
  17. El-Remessy, A. B., Abou-Mohamed, G., Caldwell, R. W., and Caldwell, R. B., High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. Invest. Ophthalmol. Vis. Sci., 44, 3135–3143 (2003).CrossRefPubMedGoogle Scholar
  18. Ferris, F. L. 3rd, Fine, S. L., and Hyman, L., Age-related macular degeneration and blindness due to neovascular maculopathy. Arch. Ophthalmol., 102, 1640–1642 (1984).PubMedGoogle Scholar
  19. Folkman, J., Angiogenesis. Annu. Rev. Med., 57, 1–18 (2006).CrossRefPubMedGoogle Scholar
  20. Frank, R. N., Diabetic retinopathy. N. Engl. J. Med., 350, 48–58 (2004).CrossRefPubMedGoogle Scholar
  21. Friedman, D. S., O’Colmain, B. J., Munoz, B., Tomany, S. C., Mccarty, C., De Jong, P. T., Nemesure, B., Mitchell, P., and Kempen, J., Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol., 122, 564–572 (2004).CrossRefPubMedGoogle Scholar
  22. Funatsu, H., Yamashita, H., Noma, H., Mimura, T., Yamashita, T., and Hori, S., Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am. J. Ophthalmol., 133, 70–77 (2002).CrossRefPubMedGoogle Scholar
  23. Gariano, R. F. and Gardner, T. W., Retinal angiogenesis in development and disease. Nature, 438, 960–966 (2005).CrossRefPubMedGoogle Scholar
  24. Gehrs, K. M., Anderson, D. H., Johnson, L. V., and Hageman, G. S., Age-related macular degeneration-emerging pathogenetic and therapeutic concepts. Ann. Med., 38, 450–471 (2006).CrossRefPubMedGoogle Scholar
  25. Gilbert, C., Rahi, J., Eckstein, M., O’sullivan, J., and Foster, A., Retinopathy of prematurity in middle-income countries. Lancet, 350, 12–14 (1997).CrossRefPubMedGoogle Scholar
  26. Good, W. V., Hardy, R. J., Dobson, V., Palmer, E. A., Phelps, D. L., Quintos, M., and Tung, B., The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics, 116, 15–23 (2005).CrossRefPubMedGoogle Scholar
  27. Haller, J. A., Qin, H., Apte, R. S., Beck, R. R., Bressler, N. M., Browning, D. J., Danis, R. P., Glassman, A. R., Googe, J. M., Kollman, C., Lauer, A. K., Peters, M. A., and Stockman, M. E., Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology, 117, 1087–1093 e3 (2010).CrossRefPubMedGoogle Scholar
  28. Heidary, G., Vanderveen, D., and Smith, L. E., Retinopathy of prematurity: current concepts in molecular pathogenesis. Semin. Ophthalmol., 24, 77–81 (2009).CrossRefPubMedGoogle Scholar
  29. Hellberg, C., Ostman, A., and Heldin, C. H., PDGF and vessel maturation. Recent Results Cancer Res., 180, 103–114 (2010).CrossRefPubMedGoogle Scholar
  30. Hellstrom, A., Perruzzi, C., Ju, M., Engstrom, E., Hard, A. L., Liu, J. L., Albertsson-Wikland, K., Carlsson, B., Niklasson, A., Sjodell, L., Leroith, D., Senger, D. R., and Smith, L. E., Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc. Natl. Acad. Sci. U.S.A., 98, 5804–5808 (2001).CrossRefPubMedGoogle Scholar
  31. Hubbard, G. B. 3rd, Surgical management of retinopathy of prematurity. Curr. Opin. Ophthalmol., 19, 384–390 (2008).CrossRefPubMedGoogle Scholar
  32. Jager, R. D., Mieler, W. F., and Miller, J. W., Age-related macular degeneration. N. Engl. J. Med., 358, 2606–2617 (2008).CrossRefPubMedGoogle Scholar
  33. Joussen, A. M., Doehmen, S., Le, M. L., Koizumi, K., Radetzky, S., Krohne, T. U., Poulaki, V., Semkova, I., and Kociok, N., TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol. Vis., 15, 1418–1428 (2009).PubMedGoogle Scholar
  34. Jung, Y. J., Isaacs, J. S., Lee, S., Trepel, J., and Neckers, L., IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J., 17, 2115–2117 (2003).PubMedGoogle Scholar
  35. Kaiser, P. K., Vascular endothelial growth factor Trap-Eye for diabetic macular oedema. Br. J. Ophthalmol., 93, 135–136 (2009).CrossRefPubMedGoogle Scholar
  36. Kempen, J. H., O’Colmain, B. J., Leske, M. C., Haffner, S. M., KleIn, R., Moss, S. E., Taylor, H. R., and Hamman, R. F., The prevalence of diabetic retinopathy among adults in the United States. Arch. Ophthalmol., 122, 552–563 (2004).CrossRefPubMedGoogle Scholar
  37. Kim, J. H., Khwarg, S. I., Choung, H. K., and Yu, Y. S., Management of porous polyethylene implant exposure in patients with retinoblastoma following enucleation. Ophthalmic Surg. Lasers Imaging, 35, 446–452 (2004).PubMedGoogle Scholar
  38. Kim, J. H., Park, J. A., Lee, S. W., Kim, W. J., Yu, Y. S., and Kim, K. W., Blood-neural barrier: intercellular communication at glio-vascular interface. J. Biochem. Mol. Biol., 39, 339–345 (2006).PubMedGoogle Scholar
  39. Kim, J. H., Yu, Y. S., Shin, J. Y., Lee, H. Y., and Kim, K. W., Deguelin inhibits retinal neovascularization by downregulation of HIF-1alpha in oxygen-induced retinopathy. J. Cell. Mol. Med., 12, 2407–2415 (2008).CrossRefPubMedGoogle Scholar
  40. Kim, J. H., Lee, Y. M., Ahn, E. M., Kim, K. W., and Yu, Y. S., Decursin inhibits VEGF-mediated inner blood-retinal barrier breakdown by suppression of VEGFR-2 activation. J. Cereb. Blood Flow Metab., 29, 1559–1567 (2009a).CrossRefPubMedGoogle Scholar
  41. Kim, J. H., Oh, M., Yu, Y. S., Kim, K. W., and Kwon, H. J., N-hydroxy-7-(2-naphthylthio) heptanomide inhibits retinal and choroidal angiogenesis. Mol. Pharm., 6, 513–519 (2009b).CrossRefPubMedGoogle Scholar
  42. Kim, J. H., Jun, H. O., Yu, Y. S., and Kim, K. W., Inhibition of protein kinase C delta attenuates blood-retinal barrier breakdown in diabetic retinopathy. Am. J. Pathol., 176, 1517–1524 (2010).CrossRefPubMedGoogle Scholar
  43. Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J. E., Lee, S. W., Moon, E. J., Kim, H. S., Lee, S. K., Chung, H. Y., Kim, C. W., and Kim, K. W., Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med., 7, 437–443 (2001).CrossRefPubMedGoogle Scholar
  44. Klein, R., Peto, T., Bird, A., and Vannewkirk, M. R., The epidemiology of age-related macular degeneration. Am. J. Ophthalmol., 137, 486–495 (2004).CrossRefPubMedGoogle Scholar
  45. Kliffen, M., Sharma, H. S., Mooy, C. M., Kerkvliet, S., and De Jong, P. T., Increased expression of angiogenic growth factors in age-related maculopathy. Br. J. Ophthalmol., 81, 154–162 (1997).CrossRefPubMedGoogle Scholar
  46. Kvanta, A., Steen, B., and Seregard, S., Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma. Exp. Eye Res., 63, 511–518 (1996).CrossRefPubMedGoogle Scholar
  47. Lee, S. Y., Kim, D. K., Cho, J. H., Koh, J. Y., and Yoon, Y. H., Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma. Arch. Ophthalmol., 126, 953–958 (2008).CrossRefPubMedGoogle Scholar
  48. Lin, P. and O’Brien, J. M., Frontiers in the management of retinoblastoma. Am. J. Ophthalmol., 148, 192–198 (2009).CrossRefPubMedGoogle Scholar
  49. Lopez, P. F., Sippy, B. D., Lambert, H. M., Thach, A. B., and Hinton, D. R., Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci., 37, 855–868 (1996).PubMedGoogle Scholar
  50. Mantagos, I. S., Vanderveen, D. K., and Smith, L. E., Emerging treatments for retinopathy of prematurity. Semin. Ophthalmol., 24, 82–86 (2009).CrossRefPubMedGoogle Scholar
  51. Mintz-Hittner, H. A., Avastin as monotherapy for retinopathy of prematurity. J. AAPOS, 14, 2–3 (2010).CrossRefPubMedGoogle Scholar
  52. Miyamoto, N., De Kozak, Y., Normand, N., Courtois, Y., Jeanny, J. C., Benezra, D., and Behar-Cohen, F., PlGF-1 and VEGFR-1 pathway regulation of the external epithelial hemato-ocular barrier. A model for retinal edema. Ophthalmic Res., 40, 203–207 (2008).CrossRefPubMedGoogle Scholar
  53. Mousa, S. A. and Mousa, S. S., Current status of vascular endothelial growth factor inhibition in age-related macular degeneration. BioDrugs, 24, 183–194 (2010).CrossRefPubMedGoogle Scholar
  54. Ni, Z. and Hui, P., Emerging pharmacologic therapies for wet age-related macular degeneration. Ophthalmologica, 223, 401–410 (2009).CrossRefPubMedGoogle Scholar
  55. Oh, S. H., Woo, J. K., Yazici, Y. D., Myers, J. N., Kim, W. Y., Jin, Q., Hong, S. S., Park, H. J., Suh, Y. G., Kim, K. W., Hong, W. K., and Lee, H. Y., Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J. Natl. Cancer Inst., 99, 949–961 (2007).CrossRefPubMedGoogle Scholar
  56. Ozkiris, A., Anti-VEGF agents for age-related macular degeneration. Expert Opin. Ther. Pat., 20, 103–118 (2010).CrossRefPubMedGoogle Scholar
  57. Palmer, E. A., Flynn, J. T., Hardy, R. J., Phelps, D. L., Phillips, C. L., Schaffer, D. B., and Tung, B., Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology, 98, 1628–1640 (1991).PubMedGoogle Scholar
  58. Penn, J. S., Madan, A., Caldwell, R. B., Bartoli, M., Caldwell, R. W., and Hartnett, M. E., Vascular endothelial growth factor in eye disease. Prog. Retin. Eye Res., 27, 331–371 (2008).CrossRefPubMedGoogle Scholar
  59. PIna, Y., Boutrid, H., Schefler, A., Dubovy, S., Feuer, W., Jockovich, M. E., and Murray, T. G., Blood vessel maturation in retinoblastoma tumors: spatial distribution of neovessels and mature vessels and its impact on ocular treatment. Invest. Ophthalmol. Vis. Sci., 50, 1020–1024 (2009).CrossRefPubMedGoogle Scholar
  60. Pugh, C. W. and Ratcliffe, P. J., Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med., 9, 677–684 (2003).CrossRefPubMedGoogle Scholar
  61. Quiram, P. A. and Capone, A. Jr., Current understanding and management of retinopathy of prematurity. Curr. Opin. Ophthalmol., 18, 228–234 (2007).CrossRefPubMedGoogle Scholar
  62. Repka, M. X., Tung, B., Good, W. V., Shapiro, M., Capone, A., Jr., Baker, J. D., Barr, C. C., Phelps, D. L., and Van Heuven, W. A., Outcome of eyes developing retinal detachment during the early treatment for retinopathy of prematurity study (ETROP). Arch. Ophthalmol., 124, 24–30 (2006).CrossRefPubMedGoogle Scholar
  63. Ricart, A. D., Tolcher, A. W., Liu, G., Holen, K., Schwartz, G., Albertini, M., Weiss, G., Yazji, S., Ng, C., and Wilding, G., Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin. Cancer Res., 14, 7924–7929 (2008).CrossRefPubMedGoogle Scholar
  64. Rishi, E., Rishi, P., Ratra, D., and Bhende, M., Off-label use of bevacizumab in retinopathy of prematurity. Retina, 29, 284; author reply 284–285 (2009).CrossRefPubMedGoogle Scholar
  65. Sapieha, P., Hamel, D., Shao, Z., Rivera, J. C., Zaniolo, K., Joyal, J. S., and Chemtob, S., Proliferative retinopathies: angiogenesis that blinds. Int. J. Biochem. Cell Biol., 42, 5–12 (2010).CrossRefPubMedGoogle Scholar
  66. Sato, T., Kusaka, S., Shimojo, H., and Fujikado, T., Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. Ophthalmology, 116, 2165–2169 (2009).CrossRefPubMedGoogle Scholar
  67. Schofield, C. J. and Ratcliffe, P. J., Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol., 5, 343–354 (2004).CrossRefPubMedGoogle Scholar
  68. Sfikakis, P. P., Markomichelakis, N., Theodossiadis, G. P., Grigoropoulos, V., Katsilambros, N., and Theodossiadis, P. G., Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab. Diabetes Care, 28, 445–447 (2005).CrossRefPubMedGoogle Scholar
  69. Shen, J., Samul, R., Silva, R. L., Akiyama, H., Liu, H., Saishin, Y., Hackett, S. F., Zinnen, S., Kossen, K., Fosnaugh, K., Vargeese, C., Gomez, A., Bouhana, K., Aitchison, R., Pavco, P., and Campochiaro, P. A., Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther., 13, 225–234 (2006).CrossRefPubMedGoogle Scholar
  70. Shields, C. L., Shields, J. A., Baez, K. A., Cater, J., and De Potter, P. V., Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors. Br. J. Ophthalmol., 77, 544–548 (1993).CrossRefPubMedGoogle Scholar
  71. Shields, C. L., Shields, J. A., Baez, K., Cater, J. R., and De Potter, P., Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors. Cancer, 73, 692–698 (1994).CrossRefPubMedGoogle Scholar
  72. Singerman, L., Combination therapy using the small interfering RNA bevasiranib. Retina, 29, S49-S50 (2009).Google Scholar
  73. Slakter, J. S., Anecortave acetate for treating or preventing choroidal neovascularization. Ophthalmol. Clin. North Am., 19, 373–380 (2006).PubMedGoogle Scholar
  74. Smiddy, W. E. and Flynn, H. W. Jr., Vitrectomy in the management of diabetic retinopathy. Surv. Ophthalmol., 43, 491–507 (1999).CrossRefPubMedGoogle Scholar
  75. Stitt, A. W., Simpson, D. A., Boocock, C., Gardiner, T. A., Murphy, G. M., and Archer, D. B., Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. J. Pathol., 186, 306–312 (1998).CrossRefPubMedGoogle Scholar
  76. Thurman, J. M., Renner, B., Kunchithapautham, K., Ferreira, V. P., Pangburn, M. K., Ablonczy, Z., Tomlinson, S., Holers, V. M., and Rohrer, B., Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury. J. Biol. Chem., 284, 16939–16947 (2009).CrossRefPubMedGoogle Scholar
  77. Tian, N., Visual experience and maturation of retinal synaptic pathways. Vision Res., 44, 3307–3316 (2004).CrossRefPubMedGoogle Scholar
  78. Tolentino, M. J., Current molecular understanding and future treatment strategies for pathologic ocular neovascularization. Curr. Mol. Med., 9, 973–981 (2009).CrossRefPubMedGoogle Scholar
  79. Weis, S. M. and Cheresh, D. A., Pathophysiological consequences of VEGF-induced vascular permeability. Nature, 437, 497–504 (2005).CrossRefPubMedGoogle Scholar
  80. Zahn, G., Vossmeyer, D., Stragies, R., Wills, M., Wong, C. G., Loffler, K. U., Adamis, A. P., and Knolle, J., Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. Arch. Ophthalmol., 127, 1329–1335 (2009).CrossRefPubMedGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea and Springer Netherlands 2010

Authors and Affiliations

  • Dong Hyun Jo
    • 1
    • 2
  • Jin Hyoung Kim
    • 2
  • Jeong Hun Kim
    • 1
    • 2
    • 3
  1. 1.Department of Ophthalmology, College of MedicineSeoul National UniversitySeoulKorea
  2. 2.Fight against Angiogenesis-Related Blindness (FARB) laboratory, Department of Ophthalmology, College of MedicineSeoul National UniversitySeoulKorea
  3. 3.FARB (Fight against Angiogenesis-Related Blindness) Laboratory, Department of OphthalmologySeoul National University College of Medicine and Seoul Artificial Eye Center, Clinical Research Institute, Seoul National University HospitalSeoulKorea

Personalised recommendations